000			05075nam a2200421 i 4500
999			_c362864 _d362864 _x1
001			362864
003			ES-MaUEC
005			20230102121626.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			210530s2021 gw | o |||| 0|eng d
020			_a9783030707736
024	7		_a10.1007/978-3-030-70773-6 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC280.L5 _b2021 EB
245	0	0	_aLiver Intra-arterial PRRT with 111In-Octreotide : _bThe Tumoricidal Efficacy of 111In Auger Electron Emission _cedited by Georgios S. Limouris
250			_aFirst edition 2021
264		1	_aCham _bSpringer International Publishing _c2021
300			_a1 recurso en línea (XIII, 270 páginas) _b130 ilustraciones, 124 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aArchivo de texto _bPDF
505	0		_aThe efficacy of auger and internal conversion electron emission 0f in-111 to treat neuroendocrine tumors -- Somatostatin -- Gastro-entero-pancreatic neuroendocrine tumors -- [111in-dtpa0-d-phe1] - octreotide: the ligand -the receptor-label -- Regulations and requirements of hospitals performing radio-infusions -- Intravenous radio-peptide infusion with in-octreotide -- Intra-arterial radio-peptide infusion -- Radio-peptide infusions after implementation of an intra-arterial port system -- US, CT and MRI for the evaluation of patients with neuroendocrine tumors -- Angiographic anatomy on the course of liver intra-arterial infusion -- Liver radio-infusions: identifying anatomic variants -- Dosimetry and dose calculation: its necessity in radio-peptide therapy -- Evaluation and assessment of the radio-peptide treatment efficacy -- Intra-venous radio-peptide infusions with in-octreotide for the treatment of bronchial carcinoids -- Intra-arterial radio - peptide infusions for the treatment of colorectal carcinomas -- Intra-arterial radio-peptide infusions for the treatment of paragangliomas -- Intra-arterial radio-peptide infusions for the treatment of brain meningiomas -- Surgery in neuroendocrine tumors -- Cytoreductive surgery combined with intraperitoneal [111in-dtpa0- d-phe1]-octreotide infusions in neuroendocrine character metastases -- Patients survival followed intra-arterial versus intravenous infusions -- Complications and side effects on the course of liver-radio-infusions -- Progression free survival and response rate in neuroendocrine liver-metastasized patients, treated with in-111 octreotide -- Therapy response vs variability of tumor size, absorbed dose, and ki-67 index after in-111 octreotide intra-arterial infusions.
520			_aThis book describes in detail a clinical project that reveals the tumoricidal efficacy of Auger and internal conversion electrons, emitted from n.c.a. 111In and implemented in oncology as a treating armamentarium for peptide receptor radionuclide therapy (PRRT), targeting small size (ø ≤ 20 mm) tumors and micro-metastases. The keen interest in n.c.a. 111In began when it was observed that its Auger electron emission could be highly radiotoxic, due to its high LET when it decayed in the vicinity of cellular DNA. The somatostatin analog octreotide, labeled with [111In-diethylenetriaminepentaacetic acid (DTPA0-D-Phe1)] is an established diagnostic agent for the imaging of somatostatin receptor-positive neuro- (or non-neuro) endocrine tumors. It relies on receptor-mediated binding, internalization and installation in the lysosomes in the proximity of the nucleus; administered in large doses, loco-regionally, via the feeding artery of solid tumors, can be highly radiotoxic if they over-express somatostatin receptors, mainly of the sst2 histotype. The book compares the results between i.v. and i.a. implementation in more than 80 patients after over 800 i.a. infusions in neuroendocrine tumors, meningiomas, paragangliomas and colorectal carcinomas in a single Institute (Aretaieion University Hospital) and encourages the i.a. way, leading to "tumor melting", while minimizing the toxicity to healthy peritumoral liver tissue and critical organs (kidneys and bone marrow). The volume is an invaluable tool for nuclear medicine physicians, interventional radiologists and oncologists dealing with radiopeptide therapies. .
988			_aSpringer_Medicine_2021
650		7	_2embne _9413204 _aHígado _xCáncer
700	1		_aLimouris, Georgios S. _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030707729
776	0	8	_iPrinted edition: _z9783030707743
776	0	8	_iPrinted edition: _z9783030707750
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-70773-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b02/2022 _dz _eb _zSI